Latest Conference Articles

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.